China Patent Accepted for RECCE Anti-Infectives
Filed with ASX · · 3 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Recce Enters into USA Department of Defense R&D Agreement
- Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections
- Entitlement Offer - Offer Booklet and Access Letter
- Phase II Clinical Trial Receives Additional Approval for DFI
- Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
Later from Recce Pharmaceuticals
- Successful Placement of Entitlement Offer Shortfall
- Recce Signs Debt Facility with Avenue Capital Group
- R327G Highly Effective in Burn Wounds Model
- Preliminary Final Report
- Patient Dosing Underway in Ph 3 Indonesia DFI Trial
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals